Managed care controls could allow for more relaxed FDA approval standards, Covance exec maintains.
Executive Summary
MANAGED CARE DRUG CONTROLS MAKE ACCELERATED APPROVAL ACCEPTABLE MODEL for a larger number of FDA reviews, Covance Senior Scientific Officer William Wardell, MD/PhD, maintained at a July 18 Capitol Hill briefing on an Institute for Alternative Futures report, "Clinical Development 2005." Managed care "with its utilization controls, its databases and potential for quick follow-up has really transformed the landscape [of drug monitoring] and possibly made some of our strictest controls redundant," Wardell suggested.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth